Albumin-binder ligands
Attaching a small chemical 'hook' that grips the body's own albumin protein makes a radioactive drug stay in the bloodstream for longer, so more of it reaches the tumour before it is cleared out through the kidneys.
Overview
Small-molecule and peptide radioligands (such as PSMA-617) are cleared from the blood within minutes to a few hours, which limits the fraction of injected activity that can diffuse into and bind tumour tissue before excretion. Conjugating an albumin-binding moiety, most commonly a truncated Evans blue (EB) dye derivative or 4-(p-iodophenyl)butyric acid (IPBA/IP), to the targeting ligand allows reversible, non-covalent binding to circulating serum albumin (biological half-life around 19 days), which extends the ligand's effective blood half-life from minutes to several hours without permanently trapping the radionuclide.
In preclinical work, Evans-blue-modified PSMA-617 (EB-PSMA-617) showed markedly extended blood retention compared with unmodified PSMA-617 and produced higher tumour uptake and greater therapeutic efficacy at lower administered activity in mouse models; a single low dose eliminated PSMA-positive tumours in one widely cited study. Albumin-binder chemistry generalises across chelator and radionuclide (86Y/90Y/177Lu-DOTA-EB-PSMA-617; 64Cu-PSMA-CM using an MPA albumin-binding moiety) and across targets (SSTR, GRPR ligands). The main design trade-off is pharmacokinetic: too strong an albumin interaction raises blood and normal-organ (especially bone marrow) dose and can worsen the therapeutic index, so linker length, albumin-binding affinity and total charge are tuned empirically for each ligand; increased kidney or hepatobiliary retention has also been reported for some albumin-binder designs and must be balanced against the gain in tumour dose.
How it works
A small chemical moiety with affinity for serum albumin (such as a truncated Evans blue dye or 4-(p-iodophenyl)butyric acid) is attached to the radioligand; it binds albumin reversibly, piggy-backing on the protein's long circulating half-life so the ligand stays in the bloodstream, and therefore available to bind the tumour, for hours instead of minutes.
Dependencies
Open the dependency map →Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Latest papers
topQuery for this technology: (TITLE:"Albumin-binder ligands" OR ABSTRACT:"Albumin-binder ligands" OR TITLE:"albumin-binding moiety" OR ABSTRACT:"albumin-binding moiety" OR TITLE:"Evans blue conjugate" OR ABSTRACT:"Evans blue conjugate" OR TITLE:"IPBA conjugate" OR ABSTRACT:"IPBA conjugate") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Albumin-binder ligands, not a curated reading list.
Similar pages
not linked directly; found by shared links- TechnologyRadiohybrid (rh) chemistry
Shares DOTA chelation, Lutetium-177 and the tags chemistry, PSMA.
- CompanyNuclidium
Shares Copper-64, PSMA, Lutetium-177 and the tag PSMA.
- TechnologySarcophagine chelation
Shares DOTA chelation, Copper-64 and the tag chemistry.
- CompanyNucleus RadioPharma
- CompanyMIM Software (GE HealthCare)
Shares Yttrium-90, Radioligand therapy (beta emitters), Lutetium-177.
- CompanyARTBIO
Shares PSMA, Radioligand therapy (beta emitters), Lutetium-177.
- TermLigand
Shares PSMA, Radioligand therapy (beta emitters).
- TermChelator (bifunctional chelating agent)
Shares Yttrium-86, Copper-64, Yttrium-90, Lutetium-177.